Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Regeneron Pharmaceuticals is conducting a Phase 1/2 study titled A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors. The study aims to assess the safety, tolerability, and optimal dosing of REGN7075 alone and in combination with cemiplimab, with or without chemotherapy, in patients with advanced solid tumors. The significance lies in its potential to enhance cancer treatment efficacy by controlling tumor cell proliferation.
Intervention/Treatment: The study tests the investigational drug REGN7075, used alone or with cemiplimab, and sometimes with chemotherapy. REGN7075 is administered via intravenous or subcutaneous injection, aiming to improve cancer treatment outcomes.
Study Design: This interventional study is non-randomized and follows a sequential intervention model without masking. Its primary purpose is treatment-focused, exploring various combinations of REGN7075 and cemiplimab across different cancer types.
Study Timeline: The study began on December 21, 2020, and is currently recruiting. The last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The study’s progress could positively impact Regeneron’s stock performance, as successful outcomes may enhance its oncology portfolio. Investors should monitor competitor activities and industry trends, as advancements in cancer treatments can shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.